Verschlechtert die Gabe von rekombinantem humanem Erythropoietin die Prognose von Patienten mit Kopf-Hals-Tumoren unter Radiotherapie?

Translated title of the contribution: Is recombinant Human Erythropoietin Therapy Disadvantageous in Head and Neck Cancer Patients under Radiotherapy?

Wolfgang Jelkmann

1 Citation (Scopus)
Translated title of the contributionIs recombinant Human Erythropoietin Therapy Disadvantageous in Head and Neck Cancer Patients under Radiotherapy?
Original languageGerman
JournalStrahlentherapie und Onkologie
Volume180
Issue number3
Pages (from-to)179-180
Number of pages2
ISSN0179-7158
Publication statusPublished - 03.2004

Research Areas and Centers

  • Academic Focus: Center for Brain, Behavior and Metabolism (CBBM)

Cite this